Patients with severe acute coronary syndrome had significantly higher plasma interleukin-6 levels compared to those with non-severe disease (MD 4.97, p<0.00001).
Meta-Analysis (n=559)
Do elevated plasma IL-6 levels predict the severity of acute coronary syndrome and the occurrence of major adverse cardiovascular events?
Elevated plasma IL-6 levels are significantly associated with increased severity of acute coronary syndrome and a higher risk of major adverse cardiovascular events.
Mean Difference: 4.97 (95% CI 4.41–5.53)
p-value: p=<0.00001
This study aimed to explore the relationship between plasma interleukin 6 (IL-6) levels, adverse cardiovascular events, and the severity of acute coronary syndrome (ACS). A literature review was performed of studies regarding IL-6 and ACS extracted from databases including EMBASE, Cqvip, MEDLINE, Web of Knowledge, PubMed, Cochrane Library, China National Knowledge Infrastructure, and Wanfang data. The Newcastle-Ottawa scale (NOS) was used to evaluate the quality of the literature. The literature was screened, its quality was evaluated, and relevant data were extracted for performing meta-analysis using RevMan software (version 5.3). A total of 524 studies were included in the initial survey. After several rounds of screening and analysis, six studies met the inclusion criteria and underwent meta-analysis using a fixed-effect model. Patients were divided into non-severe and severe groups based on the concentration of high-sensitivity C-reactive protein. Meta-analysis of the relationship between IL-6 and the severity of ACS showed that the plasma IL-6 level of patients in the severe group was significantly higher than that of patients in the non-severe group (p<0.00001). Additionally, patients with experience of major adverse cardiovascular events had significantly higher plasma IL-6 levels than did patients without experience of such events (p<0.00001). In summary, patients with ACS and high IL-6 levels tended to be in a critical condition, with a higher risk of adverse cardiovascular events and worse prognosis. Thus, IL-6 levels could indicate whether patients with ACS may have adverse cardiovascular events and determine the severity of ACS.
Yang et al. (Fri,) conducted a meta-analysis in Acute Coronary Syndrome (n=559). High interleukin-6 levels vs. Low interleukin-6 levels was evaluated on Mean difference in IL-6 levels between severe and non-severe ACS groups (MD 4.97, 95% CI 4.41-5.53, p=<0.00001). Patients with severe acute coronary syndrome had significantly higher plasma interleukin-6 levels compared to those with non-severe disease (MD 4.97, p<0.00001).